The oral cavity forms an indispensable part of the human microbiome, for its unique and diverse microflora, which includes up to approximately 100 species of bacteria, fungi, viruses, archaea and protozoa. Some of these bacteria are implicated in the pathogenesis of oral diseases such as caries and periodontitis; Porphyromonas gingivalis is a main etiological factor in periodontal diseases.
EPO’s new patented extract Planoràl is a unique blend of Skullcap (Scutellaria lateriflora L.) and Cistus (Cistus x incanus L.), acting as antibacterial against Porphyromonas gingivalis to prevent periodontitis.
The efficacy of Planoràl is also proved by the induction of beta-defensins release with and without the presence of inflammation.
Click here to read more and download the brochure
Not too long ago, literature evidence began to suggest a link between chronic oral inflammation and some systemic diseases. In fact, periodontitis is a constant potential source of infection and inflammation, and it has been considered a separate risk factor for cardiovascular, cerebrovascular and respiratory diseases, as well as a potential risk for increased morbidity and mortality for diabetes, insulin resistance, rheumatoid arthritis, obesity, osteoporosis and complications of pregnancy.